Madrigal Pharmaceuticals Total Debt vs. Price To Sales
| MDGL Stock | USD 312.00 1.13 0.36% |
For Madrigal Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Madrigal Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Madrigal Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Madrigal Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Madrigal Pharmaceuticals over time as well as its relative position and ranking within its peers.
Madrigal |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.03) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Madrigal Pharmaceuticals Price To Sales vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Madrigal Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Madrigal Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Madrigal Pharmaceuticals is regarded fourth in total debt category among its peers. It is rated below average in price to sales category among its peers . The ratio of Total Debt to Price To Sales for Madrigal Pharmaceuticals is about 1,327,682 . At this time, Madrigal Pharmaceuticals' Price To Sales Ratio is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Madrigal Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Madrigal Total Debt vs. Competition
Madrigal Pharmaceuticals is regarded fourth in total debt category among its peers. Total debt of Health Care industry is now estimated at about 4.55 Billion. Madrigal Pharmaceuticals holds roughly 117.19 Million in total debt claiming about 2.58% of equities under Health Care industry.
Madrigal Price To Sales vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Madrigal Pharmaceuticals |
| = | 117.19 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Madrigal Pharmaceuticals |
| = | 88.27 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Madrigal Price To Sales Comparison
Madrigal Pharmaceuticals is currently under evaluation in price to sales category among its peers.
Madrigal Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Madrigal Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Madrigal Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Madrigal Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Madrigal Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 468 K | 491.4 K | |
| Operating Income | -380.5 M | -361.5 M | |
| Net Loss | -373.6 M | -354.9 M | |
| Income Tax Expense | 4.6 M | 4.8 M | |
| Income Before Tax | -373.6 M | -354.9 M | |
| Total Other Income Expense Net | 6.9 M | 7.2 M | |
| Net Loss | -373.6 M | -354.9 M | |
| Net Loss | -265.8 M | -252.5 M | |
| Interest Income | 19.6 M | 20.6 M | |
| Net Interest Income | 6.9 M | 3.8 M | |
| Non Operating Income Net Other | 2.5 M | 4.1 M | |
| Change To Netincome | 36.4 M | 38.2 M | |
| Net Loss | (19.99) | (20.99) | |
| Income Quality | 0.87 | 0.55 | |
| Net Income Per E B T | 0.91 | 0.70 |
Madrigal Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Madrigal Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Madrigal Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Madrigal Pharmaceuticals' important profitability drivers and their relationship over time.
Use Madrigal Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Madrigal Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Madrigal Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Madrigal Pharmaceuticals Pair Trading
Madrigal Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Madrigal Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Madrigal Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Madrigal Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Madrigal Pharmaceuticals to buy it.
The correlation of Madrigal Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Madrigal Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Madrigal Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Madrigal Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Madrigal Pharmaceuticals position
In addition to having Madrigal Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Raw Materials Thematic Idea Now
Raw Materials
Companies that are involved with the development and processing of raw materials such as silver or forestry. The Raw Materials theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Raw Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
To fully project Madrigal Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Madrigal Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Madrigal Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.